Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 67

Sort by

Sort Order Select

Journal Articles

Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes

Blood (2023) 141 (17): 2047–2061.

https://doi.org/10.1182/blood.2022018604

Published: 2023

Includes: Supplemental data

Journal Articles

Efficacy and Safety of Add-on Parsaclisib to Ruxolitinib Therapy in Myelofibrosis Patients With Suboptimal Response to Ruxolitinib: Final Results From a Phase 2 Study

Abdulraheem Yacoub, Uma Borate, Raajit K Rampal, Haris Ali, Eunice Wang, Aaron T. Gerds, Gabriela S. Hobbs, Marina Kremyanskaya, Elliott Winton, Casey O'Connell, Swati Goel, Stephen T Oh, Gary J. Schiller, Albert Assad, Sue Erickson-Viitanen, Feng Zhou, Naval Daver

Blood (2022) 140 (Supplement 1): 579–582.

https://doi.org/10.1182/blood-2022-160384

Published: 2022

Journal Articles

A Phase 1b Dose Escalation and Expansion Study of SNDX-5613, Azacitidine (AZA) and Venetoclax (VEN) in Newly Diagnosed, Patients ≥ 60 Years with Untreated NPM1 -Mutated/ FLT3 -Wild Type AML or KMT2A -Rearranged Acute Myeloid Leukemia (AML)

Blood (2022) 140 (Supplement 1): 9070–9073.

https://doi.org/10.1182/blood-2022-166715

Published: 2022

Journal Articles

Characterizing the Development of Secondary Myelodysplastic Syndrome (MDS) with Antecedent or Concurrent Chronic Lymphocytic Leukemia (CLL) in the Era of Small Molecule Inhibitors for the Treatment of CLL

Kristin L Koenig, Prachi Jain, Ying Huang, Kerry A. Rogers, Seema A. Bhat, Jennifer A. Woyach, Michael R. Grever, Uma Borate, Alice S. Mims, Daniel Jones, Cecelia Miller, James S. Blachly, Adam S Kittai

Blood (2022) 140 (Supplement 1): 4071–4073.

https://doi.org/10.1182/blood-2022-168274

Published: 2022

Journal Articles

Stimulus MDS-US Trial in Progress: Evaluating Sabatolimab in Combination with Hypomethylating Agents (HMAs) in Patients with Intermediate-, High-, or Very High-Risk Myelodysplastic Syndrome (MDS)

Amer M. Zeidan, Amy E. DeZern, Uma Borate, Krissy Kobata, Susan E. Ide, John Sabo, Pedro Marques Ramos, Haiying Sun, Roger M. Lyons, Guillermo Garcia-Manero

Blood (2022) 140 (Supplement 1): 4069–4070.

https://doi.org/10.1182/blood-2022-167259

Published: 2022

Journal Articles

A Phase 2 Randomized Study Comparing Venetoclax and Azacitidine to Conventional Induction Chemotherapy for Newly Diagnosed Fit Adults with Acute Myeloid Leukemia

Amir T. Fathi, Geoffrey G Fell, Areej El-Jawahri, Alexander E. Perl, Brian A. Jonas, Ajoy L. Dias, Alice S. Mims, Uma Borate, Brittany Knick Ragon, Michael R. Grunwald, Mary Linton B. Peters, Timothy A. Graubert, Philip C. Amrein, Hanno R. Hock, Andrew M. Brunner, Gabriela S. Hobbs, Rupa Narayan, Donna S. Neuberg, Ibrahim Aldoss

Blood (2022) 140 (Supplement 1): 3284–3286.

https://doi.org/10.1182/blood-2022-162525

Published: 2022

Journal Articles

Entospletinib (ENTO) in Combination with Cytarabine (Ara-C) and Daunorubicin (DNR) in Newly Diagnosed (ND) Adult Patients with NPM1 -Mutated and FLT3 -ITD Wild-Type Acute Myeloid Leukemia (AML) Is Associated with Good Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial

Blood (2022) 140 (Supplement 1): 6200–6203.

https://doi.org/10.1182/blood-2022-167316

Published: 2022

Journal Articles

A Risk-Adapted Study to Assess the Efficacy of Enasidenib and Subsequent Response-Driven Addition of Azacitidine for Newly Diagnosed IDH2 -Mutant AML Patients: 3-Year Follow-up

Blood (2022) 140 (Supplement 1): 2016–2019.

https://doi.org/10.1182/blood-2022-166850

Published: 2022

Journal Articles

Is Disease Response a Patient-Centered Clinical Trial Endpoint in Acute Myeloid Leukemia: Differences in Symptom Burden and Physical Function By Response Status in the Beat-AML Master Trial

Antonia V. Bennett, Xianming Tan, Matthew C. Foster, Daniel R. Richardson, Ashley L. Bryant, William A. Wood, Jr., Ashley O. Yocum, Alice S. Mims, Uma Borate, Amy Burd

Blood (2022) 140 (Supplement 1): 3367–3368.

https://doi.org/10.1182/blood-2022-160426

Published: 2022

Journal Articles

Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AML

Blood (2022) 139 (8): 1208–1221.

https://doi.org/10.1182/blood.2021011354

Published: 2022

Includes: Supplemental data

Journal Articles

Effect of High Intensity Chemotherapy Vs Targeted Therapy on Survival in AML Patients Aged 60-75

Kieran D Sahasrabudhe, Melanie T Rebechi, Ying Huang, Greg K. Behbehani, Bhavana Bhatnagar, James S. Blachly, Bradley W Blaser, Uma Borate, Ramiro Garzon, Tamanna Haque, Karilyn Larkin, Meixiao Long, Alice S. Mims, Ayman Saad, Sumithira Vasu, Alison R. Walker, Sarah A Wall

Blood (2021) 138 (Supplement 1): 4125.

https://doi.org/10.1182/blood-2021-148676

Published: 2021

Journal Articles

Ivosidenib (IVO) in Combination with Azacitidine (AZA) in Newly Diagnosed (ND) Older Patients with IDH1 R132-Mutated Acute Myeloid Leukemia (AML) Induces High Response Rates: A Phase 2 Sub-Study of the Beat AML Master Trial

Blood (2021) 138 (Supplement 1): 875.

https://doi.org/10.1182/blood-2021-149115

Published: 2021

Journal Articles

Final Results of a Phase 1b Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Alice S. Mims, Melhem Solh, Jennifer N. Saultz, Uma Borate, Naveen Pemmaraju, Gautam Borthakur, Gail J. Roboz, Ben Powell, Bernice Matusow, Jason Halladay, Shireen Vali, Chelsea L. Hope, Madan G. Kundu, Ching Hsu, Paul Watkins, Chao Zhang, Jackie M. Walling, Athanasios C. Tsiatis, Amy E. DeZern

Blood (2021) 138 (Supplement 1): 3420.

https://doi.org/10.1182/blood-2021-152040

Published: 2021

Journal Articles

A Retrospective Observational Real-World Study of the Characteristics, Genomic Analysis, Treatment Patterns and Outcomes of Patients (Pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) in the United States

John C. Byrd, Jennifer L Gatz, Larry D. Cripe, , Cynthia Lim Louis, Alice S. Mims, Uma Borate, Ashley O. Yocum, Theophilus Gana, Amy Burd

Blood (2021) 138 (Supplement 1): 3383.

https://doi.org/10.1182/blood-2021-153926

Published: 2021

Journal Articles

Venetoclax and Azacitidine in the Treatment of Patients with Relapsed/Refractory Myelodysplastic Syndrome

Amer M. Zeidan, Uma Borate, Daniel A. Pollyea, Andrew M. Brunner, Fernando Roncolato, Jacqueline S. Garcia, Robin J Filshie, Olatoyosi Odenike, Anne-Marie Watson, Ravi Krishnadasan, Ashish Bajel, Kiran Naqvi, Jiuhong Zha, Leah Hogdal, Ying Zhou, David Hoffman, Steve Kye, Guillermo Garcia-Manero

Blood (2021) 138 (Supplement 1): 537.

https://doi.org/10.1182/blood-2021-145646

Published: 2021

Journal Articles

Venetoclax Plus Azacitidine (VEN-AZA) Vs. Intensive Chemotherapy (IC) As Induction for Patients with Acute Myeloid Leukemia (AML): Retrospective Analysis of an Electronic Medical Records (EMR) Database in the United States

Amer M. Zeidan, Daniel A. Pollyea, Uma Borate, Alberto Vasconcelos, Ravi Potluri, David Rotter, Zephirin Kiendrebeogo, Lona Gaugler, Gaetano Bonifacio, Clara Chen

Blood (2021) 138 (Supplement 1): 277.

https://doi.org/10.1182/blood-2021-147926

Published: 2021

Journal Articles

FLT3-Mutated Acute Myeloid Leukemia Using a Novel Regimen of Gemtuzumab Ozogamicin and Midostaurin in Combination with Standard Cytarabine and Daunorubicin Induction Therapy

Uma Borate, Andy Kaempf, Jessica Minnier, Shikha Misra, Shaun Goodyear, Gabrielle Meyers, Jennifer N. Saultz, Elie Traer, Ronan Swords, Rachel J. Cook, Sammantha Avaylon, Melissa Mackey, Brianna Norris, Roland B. Walter

Blood (2021) 138 (Supplement 1): 1269.

https://doi.org/10.1182/blood-2021-152791

Published: 2021

Journal Articles

Gilteritinib (GILT) Monotherapy with Addition of Decitabine (DEC) in Non-Responders in Older Newly Diagnosed (ND) FLT3 Mutated Acute Myeloid Leukemia (AML) Patients Having High and Low Variant Allele Frequency (VAF): A Phase 2/1b Sub-Study of the Beat AML Master Trial

Blood (2021) 138 (Supplement 1): 1277.

https://doi.org/10.1182/blood-2021-148207

Published: 2021

Journal Articles

Entospletinib (ENTO) and Decitabine (DEC) Combination Therapy in Older Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Patients with Mutant TP53 or Complex Karyotype Is Associated with Poor Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial

Blood (2021) 138 (Supplement 1): 1279.

https://doi.org/10.1182/blood-2021-151234

Published: 2021

Journal Articles

Subgroup Analysis from a Phase 2 Study of the Efficacy and Safety of Parsaclisib, a Selective PI3Kδ Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis (MF)

Abdulraheem Yacoub, Uma Borate, Raajit Rampal, Haris Ali, Eunice S. Wang, Aaron T. Gerds, Gabriela Hobbs, Marina Kremyanskaya, Elliott Winton, Casey O'Connell, Swati Goel, Stephen Oh, Gary J. Schiller, Albert Assad, Sue Erickson-Viitanen, Feng Zhou, Naval Daver

Blood (2021) 138 (Supplement 1): 3647.

https://doi.org/10.1182/blood-2021-148668

Published: 2021

NARROW

Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes

Efficacy and Safety of Add-on Parsaclisib to Ruxolitinib Therapy in Myelofibrosis Patients With Suboptimal Response to Ruxolitinib: Final Results From a Phase 2 Study

A Phase 1b Dose Escalation and Expansion Study of SNDX-5613, Azacitidine (AZA) and Venetoclax (VEN) in Newly Diagnosed, Patients ≥ 60 Years with Untreated NPM1 -Mutated/ FLT3 -Wild Type AML or KMT2A -Rearranged Acute Myeloid Leukemia (AML)

Characterizing the Development of Secondary Myelodysplastic Syndrome (MDS) with Antecedent or Concurrent Chronic Lymphocytic Leukemia (CLL) in the Era of Small Molecule Inhibitors for the Treatment of CLL

Stimulus MDS-US Trial in Progress: Evaluating Sabatolimab in Combination with Hypomethylating Agents (HMAs) in Patients with Intermediate-, High-, or Very High-Risk Myelodysplastic Syndrome (MDS)

A Phase 2 Randomized Study Comparing Venetoclax and Azacitidine to Conventional Induction Chemotherapy for Newly Diagnosed Fit Adults with Acute Myeloid Leukemia

Entospletinib (ENTO) in Combination with Cytarabine (Ara-C) and Daunorubicin (DNR) in Newly Diagnosed (ND) Adult Patients with NPM1 -Mutated and FLT3 -ITD Wild-Type Acute Myeloid Leukemia (AML) Is Associated with Good Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial

A Risk-Adapted Study to Assess the Efficacy of Enasidenib and Subsequent Response-Driven Addition of Azacitidine for Newly Diagnosed IDH2 -Mutant AML Patients: 3-Year Follow-up

Is Disease Response a Patient-Centered Clinical Trial Endpoint in Acute Myeloid Leukemia: Differences in Symptom Burden and Physical Function By Response Status in the Beat-AML Master Trial

Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AML

Effect of High Intensity Chemotherapy Vs Targeted Therapy on Survival in AML Patients Aged 60-75

Ivosidenib (IVO) in Combination with Azacitidine (AZA) in Newly Diagnosed (ND) Older Patients with IDH1 R132-Mutated Acute Myeloid Leukemia (AML) Induces High Response Rates: A Phase 2 Sub-Study of the Beat AML Master Trial

Final Results of a Phase 1b Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

A Retrospective Observational Real-World Study of the Characteristics, Genomic Analysis, Treatment Patterns and Outcomes of Patients (Pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) in the United States

Venetoclax and Azacitidine in the Treatment of Patients with Relapsed/Refractory Myelodysplastic Syndrome

Venetoclax Plus Azacitidine (VEN-AZA) Vs. Intensive Chemotherapy (IC) As Induction for Patients with Acute Myeloid Leukemia (AML): Retrospective Analysis of an Electronic Medical Records (EMR) Database in the United States

FLT3-Mutated Acute Myeloid Leukemia Using a Novel Regimen of Gemtuzumab Ozogamicin and Midostaurin in Combination with Standard Cytarabine and Daunorubicin Induction Therapy

Gilteritinib (GILT) Monotherapy with Addition of Decitabine (DEC) in Non-Responders in Older Newly Diagnosed (ND) FLT3 Mutated Acute Myeloid Leukemia (AML) Patients Having High and Low Variant Allele Frequency (VAF): A Phase 2/1b Sub-Study of the Beat AML Master Trial

Entospletinib (ENTO) and Decitabine (DEC) Combination Therapy in Older Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Patients with Mutant TP53 or Complex Karyotype Is Associated with Poor Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial

Subgroup Analysis from a Phase 2 Study of the Efficacy and Safety of Parsaclisib, a Selective PI3Kδ Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis (MF)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only